What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Heart failure
- Cardiology
His main research concerns Heart failure, Internal medicine, Cardiology, Ejection fraction and Intensive care medicine.
His research integrates issues of Serelaxin, Placebo, Heart disease and Blood pressure in his study of Heart failure.
The Internal medicine study which covers Endocrinology that intersects with Receptor.
The study incorporates disciplines such as Rolofylline, Systole and Renal function in addition to Cardiology.
His Ejection fraction research integrates issues from Anesthesia, Cohort and Confidence interval.
The concepts of his Intensive care medicine study are interwoven with issues in Clinical trial and Nesiritide.
His most cited work include:
- Effect of nesiritide in patients with acute decompensated heart failure. (942 citations)
- Effect of nesiritide in patients with acute decompensated heart failure. (942 citations)
- Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. (826 citations)
What are the main themes of his work throughout his whole career to date?
Heart failure, Internal medicine, Cardiology, Intensive care medicine and Ejection fraction are his primary areas of study.
His studies in Heart failure integrate themes in fields like Serelaxin, Placebo, Clinical trial and Blood pressure.
His Hazard ratio, Renal function, Confidence interval, Rolofylline and Omecamtiv mecarbil investigations are all subjects of Internal medicine research.
In his study, Activator is inextricably linked to Cardiac myosin, which falls within the broad field of Cardiology.
His Intensive care medicine study combines topics from a wide range of disciplines, such as Levosimendan, Randomized controlled trial, Nesiritide and Acute decompensated heart failure.
His work deals with themes such as Stroke, Anesthesia and Warfarin, which intersect with Ejection fraction.
He most often published in these fields:
- Heart failure (100.46%)
- Internal medicine (78.90%)
- Cardiology (68.81%)
What were the highlights of his more recent work (between 2019-2021)?
- Heart failure (100.46%)
- Internal medicine (78.90%)
- Cardiology (68.81%)
In recent papers he was focusing on the following fields of study:
His primary areas of investigation include Heart failure, Internal medicine, Cardiology, Ejection fraction and Clinical trial.
His study in Heart failure is interdisciplinary in nature, drawing from both Inotrope, Placebo, Clinical endpoint and Intensive care medicine.
His work on Expert consensus as part of general Intensive care medicine research is frequently linked to Quality of life, thereby connecting diverse disciplines of science.
In general Internal medicine, his work in Kansas City Cardiomyopathy Questionnaire, Brain natriuretic peptide, Systole and Troponin is often linked to In patient linking many areas of study.
His work carried out in the field of Cardiology brings together such families of science as Serelaxin, Omecamtiv mecarbil, Randomized controlled trial and Hazard ratio.
His Ejection fraction research is multidisciplinary, incorporating elements of Cardiac function curve, Quality of life, Contractility and Isovolumic relaxation time.
Between 2019 and 2021, his most popular works were:
- Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure (45 citations)
- Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction: Rationale and Design of GALACTIC-HF (33 citations)
- Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction: Rationale and Design of GALACTIC-HF (33 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Heart failure
- Cardiology
John R. Teerlink spends much of his time researching Heart failure, Internal medicine, Cardiology, Ejection fraction and Clinical trial.
His Heart failure research includes themes of Inotrope, Placebo, Omecamtiv mecarbil and Randomized controlled trial.
His work in the fields of Internal medicine, such as Troponin, Hazard ratio and Confidence interval, overlaps with other areas such as Pandemic and Risk of infection.
His Cardiomyopathy and Heart malformation study in the realm of Cardiology connects with subjects such as Severe acute respiratory syndrome coronavirus 2 and Patient safety.
His Mildly reduced ejection fraction study in the realm of Ejection fraction interacts with subjects such as In patient.
His biological study spans a wide range of topics, including Drug development, Drug approval, Physical function and Intensive care medicine.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
